Abstract: The present invention relates to the field of disease therapy and immunology. Specifically, disclosed are an anti-CD73 antibody or an antigen-binding fragment thereof, a nucleic acid molecule encoding same, an immunoconjugate comprising same, a bispecific molecule and a pharmaceutical composition, as well as use thereof in enhancing immune response and/or treating tumors.

Abstract: The invention relates to a pharmaceutical composition containing alginate oligosaccharide diacid with formula (IV) or a pharmaceutically acceptable salt thereof, which can be used for preparing medicaments for treating Alzheimer's disease, Parkinson's disease, inflammation, pain, diabetes or vascular dementia.

Abstract: The present invention relates to a mannuronic diacid oligosaccharide composition, comprising a mannuronic diacid of Formula (III) or a pharmaceutically acceptable salt thereof, wherein n is an integer from 1 to 9, m is 0, 1 or 2, and m? is 0 or 1, and wherein the total weight of mannuronic diacids wherein n=1-5 is 80-95% of the total weight of the composition, and the ratio of the total weight of mannuronic diacids wherein n=1-3 to the total weight of mannuronic diacids wherein n=4-7 is between 1.0 and 3.5.

Abstract: The present invention relates to an alginic oligosaccharic diacid composition comprising a mannuronic diacid of Formula (IV) or a pharmaceutically acceptable salt thereof, wherein n is an integer selected from 1 to 9, m is selected from 0, 1 or 2, m? is selected from 0 or 1, and wherein the total weight of alginic oligosaccharic diacid wherein n=1-5 accounts for more than 60% of the total weight of the composition; the total weight of guluronic acids accounts for less than 50% of the total weight of the composition.

Abstract: The present invention relates to the application of mannuronic diacid oligosaccharide composition in the treatment of vascular dementia.

Abstract: The present invention relates to the use of mannuronic diacid oligosaccharide composition in the treatment of Parkinson's disease.

Abstract: The present invention relates to the use of mannuronic diacid oligosaccharide composition in the treatment of diabetes.

Abstract: The present invention relates to the use of mannuronic diacid oligosaccharide composition in the treatment of inflammation.

Abstract: The present invention relates to the use of mannuronic diacid oligosaccharide composition in the treatment of pain.

Abstract: The present invention relates to a mannuronic diacid oligosaccharide composition, comprising a mannuronic diacid of Formula (III) or a pharmaceutically acceptable salt thereof, wherein n is an integer from 1 to 9, m is 0, 1 or 2, and m? is 0 or 1, and wherein the total weight of mannuronic diacids wherein n=1-5 is 80-95% of the total weight of the composition, and the ratio of the total weight of mannuronic diacids wherein n=1-3 to the total weight of mannuronic diacids wherein n=4-7 is between 1.0 and 3.5.

Abstract: The invention belongs to the technical field of natural medicinal chemistry and quality control thereof, and relates to a method for determining the weight average molecular weight and the purity of a soluble salt of an acidic saccharide. The method comprises using metal ion content in the soluble salt of an acidic saccharide to correct the weight average molecular weight and the content of the of acid saccharide obtained by the combined use of the molecular sieve chromatography and a multi-angle laser scattering detector SEC-MALS. The method of the present invention can be used to more quickly and accurately determine the weight average molecular weight and content of acidic saccharide soluble salts.

Abstract: The present invention relates to the use of mannuronic diacid oligosaccharide composition in the treatment of pain.

Abstract: The present invention relates to a method for degrading a polysaccharide in the field of food, medicine or chemical industry. In particular, a molecular chain of the polysaccharide is broken by ozone into polysaccharides with smaller molecular weights, oligoses and/or oligosaccharides. The polysaccharides include linear or branched glycans extracted from plants, traditional Chinese medicinal materials, animals, fungi, or microorganisms and sulfated polysaccharides or esterified polysaccharides formed by sulfation or esterification thereof. As an oxidizing agent in the reaction, the ozone can be used alone or can be used under the catalysis of a base, a metal ion, hydrogen peroxide, UV light, or activated carbon to accelerate the reaction.

Abstract: The present invention relates to the use of mannuronic diacid oligosaccharide composition in the treatment of diabetes.

Abstract: The present invention relates to the use of mannuronic diacid oligosaccharide composition in the treatment of inflammation.

Abstract: The present invention relates to the application of mannuronic diacid oligosaccharide composition in the treatment of vascular dementia.

Abstract: The present invention relates to the use of mannuronic diacid oligosaccharide composition in the treatment of Parkinson's disease.

Abstract: The present invention relates to an alginic oligosaccharic diacid composition comprising a mannuronic diacid of Formula (IV) or a pharmaceutically acceptable salt thereof, wherein n is an integer selected from 1 to 9, m is selected from 0, 1 or 2, m? is selected from 0 or 1, and wherein the total weight of alginic oligosaccharic diacid wherein n=1-5 accounts for more than 60% of the total weight of the composition; the total weight of guluronic acids accounts for less than 50% of the total weight of the composition.

Abstract: The invention relates to a new method of preparing oligomannuronic diacids, important bioactives. The method utilizes oligomannuronic acids as starting materials and the target substances are obtained by acid degradation and active hypobromous acid oxidation steps. The method of preparing oligomannuronic diacids according to the invention employs moderate reaction conditions, has few side reactions, does not need further purification, achieves a yield of more than 90%, or even more than 95%, and is suitable for production with an on-line continuous reactor device, with reaction processes easy to implement automatic control.

Abstract: The present application relates to the field of medicine. The present application relates to an isolated Saposhnikovia divaricata polysaccharide and use thereof in the manufacture of a medicament for treating diabetes mellitus or hyperlipoidemia. In particular, the present application relates to an isolated Saposhnikovia divaricata polysaccharide comprising L-arabinose, D-galacturonic acid, D-mannose, D-glucose and D-galactose, wherein the molar ratio of the L-arabinose: D-galacturonic acid: D-mannose: D-glucose: D-galactose is 1-15:1-10:1-10:10-40:1-15, preferably 1-5:5-10:1-5:20-25:1-5.